OMEROS CORP Total Long-Term Debt
OMEROS CORP (OMER) had Total Long-Term Debt of $87.90 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Balance Sheet › Liabilities › Debt
us-gaap:LongTermDebt · last filed 2026-03-31
- 2025-12-31: Long-term Debt $87.90M.
- 2025-09-30: Long-term Debt $154.94M.
- 2025-06-30: Long-term Debt $154.94M.
- 2025-03-31: Long-term Debt $164.94M.
| Period end | Long-term Debt | Long-term Debt as first filed |
|---|---|---|
| 2025-12-31 | $87.90M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $154.94M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $154.94M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $164.94M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $164.90M 10-K · filed 2026-03-31 | $164.94M 10-K · filed 2025-03-31 |
| 2024-09-30 | $164.94M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $164.94M 10-Q · filed 2024-08-07 | |
| 2023-12-31 | $213.16M 10-K · filed 2024-04-01 | |
| 2023-09-30 | $316.74M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $316.25M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $315.76M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $315.29M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $314.82M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $314.36M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $313.90M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $313.46M 10-K · filed 2023-03-13 | |
| 2021-09-30 | $313.02M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $312.58M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $312.16M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $236.29M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $232.81M 10-Q · filed 2020-11-09 | |
| 2019-12-31 | $158.21M 10-Q · filed 2020-11-09 | |
| 2017-12-31 | $83.83M 10-K · filed 2018-03-01 | |
| 2016-12-31 | $80.52M 10-K · filed 2017-03-16 | |
| 2016-10-26 | $70.00M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |